Gilead trumpets data with newly-bought magrolimab in blood c...

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

Surviving COVID-19 as a bone marrow transplant patient

Jayne Snell is one of the 1.5 million people in the UK to receive a letter asking them to stay at home for three months in a bid to avoid COVID-19.

Gilead to buy immuno-oncology firm Forty Seven for $4.9bn

Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.